Daily Technical Summary Reports on Biotech Stocks -- PTC Therapeutics, Portola Pharma, Regeneron Pharma, and Seattle Genetics

NEW YORK, July 10, 2017 /PRNewswire/ --

If you want a Stock Review on PTCT, PTLA, REGN or SGEN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Biotechnology companies are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Pre-market today, DailyStockTracker.com observes the performances of the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and Seattle Genetics Inc. (NASDAQ: SGEN). Register now and get full and free access to these DailyStockTracker.com research reports at:

http://dailystocktracker.com/register/

PTC Therapeutics 

South Plainfield, New Jersey headquartered PTC Therapeutics Inc.'s shares recorded a trading volume of 430,028 shares last Friday. The stock finished the trading session 0.16% lower at $19.29. The Company's shares have surged 24.69% in the last one month, 98.25% over the previous three months, and 76.81% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 30.88% and 59.30%, respectively. Furthermore, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have a Relative Strength Index (RSI) of 80.11.

On June 30^th, 2017, PTC Therapeutics announced that, on June 27^th, 2017, it approved non-statutory stock options to purchase an aggregate of 74,750 shares of its common stock to seven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the Company's new hires' employment compensation. Access our complete research report on PTCT for free at:

http://dailystocktracker.com/registration/?symbol=PTCT

Portola Pharma 

On Friday, South San Francisco, California headquartered Portola Pharmaceuticals Inc.'s stock ended the session 1.47% higher at $58.48. A total volume of 1.02 million shares was traded, which was above their three months average volume of 980,210 shares. The Company's shares have gained 56.15% in the last one month, 59.69% over the previous three months, and 160.61% on an YTD basis. The stock is trading 40.05% above its 50-day moving average and 91.47% above its 200-day moving average. Moreover, shares of Portola Pharma, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have an RSI of 78.76.

On June 26^th, 2017, research firm Morgan Stanley reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $50 a share to $70 a share.

On July 06^th, 2017, Portola Pharma announced that Oliver Grottke, M.D., Ph.D., RWTH University Hospital Aachen, will present at the International Society on Thrombosis and Haemostasis annual meeting in Berlin, Germany on July 10^th, 2017, from 2:45 to 4:15 p.m. UTC, at the London session room. The presentation is titled, "Prevention of Exsanguination under Apixaban Anticoagulation Using Andexanet Alfa in a Polytrauma Model". The complimentary research report on PTLA can be downloaded at:

http://dailystocktracker.com/registration/?symbol=PTLA

Regeneron Pharma 

Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc.'s stock ended the day 1.29% higher at $496.50 with a total trading volume of 719,528 shares. The Company's shares have gained 3.01% in the last month, 30.84% over the previous three months, and 35.25% on an YTD basis. The stock is trading 7.64% and 24.64% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 55.09.

On June 27^th, 2017, Regeneron Pharma and Sanofi announced that the European Commission has granted marketing authorization for Kevzara® (sarilumab) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs, such as MTX. Kevzara may be used as monotherapy in case of intolerance to MTX, or when treatment with methotrexate is inappropriate. Register for free on DailyStockTracker.com and get access to the latest report on REGN at:

http://dailystocktracker.com/registration/?symbol=REGN

Seattle Genetics 

Shares in Bothell, Washington headquartered Seattle Genetics Inc. recorded a trading volume of 880,085 shares. The stock ended Friday's session 0.43% higher at $51.37. The Company's shares are trading below their 200-day moving average by 16.57%. Furthermore, shares of Seattle Genetics, which develops and commercializes targeted therapies to treat cancer worldwide, have an RSI of 31.23.

On July 06^th, 2017, Seattle Genetics announced that it will report its Q2 financial results on July 27^th, 2017, after the close of financial markets. Following the results announcement, Company management will host a conference call and webcast discussion of the results, and provide a general corporate update. The webcast may be accessed under the investors section of the Company's website. Download your free research report on SGEN at:

http://dailystocktracker.com/registration/?symbol=SGEN

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA